Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Shanghai Fosun Pharmaceutical Group CO Ltd (SFOSF)

Shanghai Fosun Pharmaceutical Group CO Ltd (SFOSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 36.92
  • Price/Book 3.12
Trade SFOSF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6200 unch
on 07/08/24
1.7000 -4.71%
on 06/24/24
+0.0500 (+3.18%)
since 06/03/24
3-Month
1.5200 +6.58%
on 04/10/24
1.7000 -4.71%
on 06/24/24
+0.1050 (+6.93%)
since 04/05/24
52-Week
1.5150 +6.93%
on 04/05/24
2.6825 -39.61%
on 07/21/23
-0.9900 (-37.93%)
since 07/07/23

Most Recent Stories

More News
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 5.62 (+2.37%)
CNCE : 8.37 (+0.12%)
KYKOF : 17.8000 (+3.19%)
SFOSF : 1.6200 (-3.14%)
KHTRF : 4.1100 (+0.49%)
ACIU : 3.91 (unch)
BMEA : 5.54 (+1.47%)

Key Turning Points

3rd Resistance Point 1.6200
2nd Resistance Point 1.6200
1st Resistance Point 1.6200
Last Price 1.6200
1st Support Level 1.6200
2nd Support Level 1.6200
3rd Support Level 1.6200

See More

52-Week High 2.6825
Fibonacci 61.8% 2.2365
Fibonacci 50% 2.0987
Fibonacci 38.2% 1.9610
Last Price 1.6200
52-Week Low 1.5150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar